PCPC Hatching Proposal For CIR Role In FDA Ingredient Review
This article was originally published in The Rose Sheet
The Personal Care Products Council has a vision for marrying the Cosmetic Ingredient Review’s expertise with FDA’s authority, which it hopes to package into reform legislation expected this year. While FDA has balked at formalizing CIR’s role under previous proposals, this one was inspired by a third-party review program for medical devices, making it potentially more palatable to the agency and lawmakers.
You may also be interested in...
While other legislative proposals to update US cosmetics regulations would have included FDA ingredient review or codified reviews from the CIR Expert Panel for Cosmetic Ingredient Safety, the Modernization of Cosmetic Regulations Act of 2022 does not. Panelists, industry and FDA reps discussed implications for CIR at the 5-6 March meeting of the group’s independent expert panel.
The Cosmetic Ingredient Review says it expects to finalize a package of “advancements” in early 2020 to highlight the independence of its Expert Panel. Driven by the Personal Care Products Council-led CIR Steering Committee, the initiative comes at a time of escalating NGO criticism and legislative proposals that would undermine the CIR program and put its future in question.
The committee's discussion draft of cosmetics reform legislation combines elements of the proposed Personal Care Products Safety Act and FDA Cosmetic Safety and Modernization Act, but most closely aligns with the former. NGOs likely will be pleased; small businesses, perhaps not so much